Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P1.13-13 Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

Journal of Thoracic Oncology

English

MA24.10 Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma

Journal of Thoracic Oncology

English

P1.11-13 Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)

Journal of Thoracic Oncology

English

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P3.16-01 a Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

Journal of Thoracic Oncology

English

P3.cr-23 Multilobar Adenocarcinoma: A Case Report and Review of the Literature of Papillary Eccrine Adenocarcinoma Presenting With Respiratory Failure

Journal of Thoracic Oncology

English

P3.15-20 Palliative Sedation in Lung Cancer Patients Whom Needs Immediate or Elective Intractable Symptom Control

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P1.13-13 Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

MA24.10 Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma

P1.11-13 Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer

P3.16-01 a Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

P3.cr-23 Multilobar Adenocarcinoma: A Case Report and Review of the Literature of Papillary Eccrine Adenocarcinoma Presenting With Respiratory Failure

P3.15-20 Palliative Sedation in Lung Cancer Patients Whom Needs Immediate or Elective Intractable Symptom Control